Gold Moves Higher; US Composite PMI Surges In August
Dow gains 400 points, Materials sector up 2.3%, Werewolf Therapeutics up 113%, S&P PMI rises to strongest level since April 2022.
Read original at benzingaStocks · News reference
Werewolf Therapeutics shares are trading lower after the company reported Q2 financial results. Weakness may have stemmed from cash pressure, reliance on one‑time revenue from Jazz asset sale, and uncertainty around management’s strategic review.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 31, 2026, 7:37 PM
- Checked
- Jul 31, 2026, 7:37 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Dow Jumps 350 Points; BJ's Wholesale Club Posts Upbeat Earnings
US stocks rise, Dow gains over 350 points as markets open Friday; Materials sector up 2%, utilities down 0.3%. BJ's Wholesale Club beats earnings expectations and raises guidance.
Read original at benzingaWerewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal
Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.
Read original at benzingaOne of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story
Werewolf Therapeutics surged after announcing a $500 million merger with Ambros Therapeutics, putting focus on Israel Englander's holding.
Read original at benzinga